190 related articles for article (PubMed ID: 24155143)
21. Optimizing management of invasive mould diseases.
Agrawal S; Hope W; Sinkó J; Kibbler C
J Antimicrob Chemother; 2011 Jan; 66 Suppl 1():i45-53. PubMed ID: 21177403
[TBL] [Abstract][Full Text] [Related]
22. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
[TBL] [Abstract][Full Text] [Related]
23. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
24. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Almyroudis NG; Segal BH
Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
[TBL] [Abstract][Full Text] [Related]
25. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.
Morrissey CO; Gilroy NM; Macesic N; Walker P; Ananda-Rajah M; May M; Heath CH; Grigg A; Bardy PG; Kwan J; Kirsa SW; Slavin M; Gottlieb T; Chen S
Intern Med J; 2014 Dec; 44(12b):1298-314. PubMed ID: 25482742
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.
Cornely OA; Aversa F; Cook P; Jones B; Michallet M; Shea T; Vallejo C
Eur J Haematol; 2011 Oct; 87(4):289-301. PubMed ID: 21752098
[TBL] [Abstract][Full Text] [Related]
27. [Prophylaxis of fungal infections in haematological patients: pro].
Glass B
Dtsch Med Wochenschr; 2010 Sep; 135(38):1870. PubMed ID: 20842607
[No Abstract] [Full Text] [Related]
28. Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey.
Sinkó J; Csomor J; Nikolova R; Lueff S; Kriván G; Reményi P; Bátai A; Masszi T
Transpl Infect Dis; 2008 Apr; 10(2):106-9. PubMed ID: 17605727
[TBL] [Abstract][Full Text] [Related]
29. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.
Sun Y; Xu L; Liu D; Zhang X; Han W; Wang Y; Chen H; Chen Y; Wang F; Wang J; Ji Y; Tang F; Liu K; Huang XJ
Clin Microbiol Infect; 2013 Nov; 19(11):1029-34. PubMed ID: 23565830
[TBL] [Abstract][Full Text] [Related]
30. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies.
Leather HL; Wingard JR
Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028
[TBL] [Abstract][Full Text] [Related]
31. Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system?
de Pauw BE; Viscoli C
J Antimicrob Chemother; 2011 Jan; 66 Suppl 1():i55-58. PubMed ID: 21177405
[TBL] [Abstract][Full Text] [Related]
32. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections.
Maschmeyer G
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i27-30. PubMed ID: 19372178
[TBL] [Abstract][Full Text] [Related]
33. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C
Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068
[TBL] [Abstract][Full Text] [Related]
34. [Mycoses and their treatment in malignant hemopathies].
Martino P; Girmenia C
Recenti Prog Med; 1999 Mar; 90(3):160-8. PubMed ID: 10228357
[TBL] [Abstract][Full Text] [Related]
35. Of yeasts and hyphae: a hematologist's approach to antifungal therapy.
Bow EJ
Hematology Am Soc Hematol Educ Program; 2006; ():361-7. PubMed ID: 17124084
[TBL] [Abstract][Full Text] [Related]
36. Antifungal prophylaxis in the haematological patient: a practical approach.
Vázquez L; Carreras E; Serrano D; Jarque I; Mensa J; Barberán J
Rev Esp Quimioter; 2012 Dec; 25(4):299-304. PubMed ID: 23303265
[TBL] [Abstract][Full Text] [Related]
37. Management of mycoses in patients with hematologic disease and cancer -- review of the literature.
Ruhnke M; Maschmeyer G
Eur J Med Res; 2002 May; 7(5):227-35. PubMed ID: 12069913
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients.
Barnes RA; White PL; Bygrave C; Evans N; Healy B; Kell J
J Clin Pathol; 2009 Jan; 62(1):64-9. PubMed ID: 19103864
[TBL] [Abstract][Full Text] [Related]
39. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.
Groll AH; Castagnola E; Cesaro S; Dalle JH; Engelhard D; Hope W; Roilides E; Styczynski J; Warris A; Lehrnbecher T; ; ; ; ;
Lancet Oncol; 2014 Jul; 15(8):e327-40. PubMed ID: 24988936
[TBL] [Abstract][Full Text] [Related]
40. Current therapeutic approaches to fungal infections in immunocompromised hematological patients.
Pagano L; Caira M; Valentini CG; Posteraro B; Fianchi L
Blood Rev; 2010 Mar; 24(2):51-61. PubMed ID: 20056300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
